Let me be direct with you, because many rarely are.
Across the pharmaceutical companies I work with — from mid-size biotechs to global top-10 players — I see the same pattern play out with unsettling regularity. An ambitious AI initiative gets greenlit. A talented data science team is assembled, or an expensive consultancy engaged. Pilots run. Dashboards are built. There are promising demos, enthusiastic steering committee presentations, and then… quiet.
To read full blog, Click here...
Write a comment ...
Imagine a tiny medicine that can travel inside your body and go straight to the sick cells. It does not harm the healthy parts of your body.What if doctors could find a disease before you even feel sick?What if treatments could change and adjust inside your body to help you heal faster?
Eularis combines AI, big data, and healthcare expertise to identify true key opinion leaders in the pharmaceutical industry. Using trusted data signals and smarter analysis, Eularish helps teams discover influential experts, improve targeting, and build stronger, evidence-based engagement strategies with confidence.
Imagine a tiny medicine that can travel inside your body and go straight to the sick cells. It does not harm the healthy parts of your body.
AI in drug development is moving beyond “failure prevention” into something much bigger: redesigning how we discover, develop, and deliver medicines. In this episode, Dr Andree Bates speaks with Vitalay Fomin of Numenos about biomarker discovery, patient stratification, and why the next breakthroughs come from breaking down data silos across diseases, modalities, and even species.
The pharmaceutical industry is undergoing a rapid transformation, driven in large part by the revolutionary potential of artificial intelligence (AI).AI helps companies study large amounts of data. It helps them find new medicines, improve clinical trials, and make better business decisions.
The pharmaceutical industry is under pressure from every direction. Faster drug development. Tighter regulations. Rising costs. Increasing expectations from patients and healthcare systems.
The AI Strategic Blueprint for Pharma, Eularis identifies a modest shift in awareness and its transformation into results through the strategic alignment of AI with business objectives, the development of an execution plan, and the establishment of business readiness.
I keep finding disruptive AI that solves healthcare marketers’ problems and delivers real ROI in the solutions. But the companies offering them have only 1 or 2 healthcare clients because the healthcare execs are unaware of them. And their existing clients would like it to remain that way, because soon, companies that do not have AI in their centre will be unable to compete.
Trust is foundational in the pharmaceutical sector. Medicines enable people to lead healthier lives, so any failure can have widespread consequences. Today, many pharmaceutical companies deploy AI agents to boost efficiency and productivity. Beforehand, they must ensure these AI agents are reliable.
AI is not just transforming industries; it is also transforming the way we compete. What used to be a luxury is now table stakes, forcing efficiency, innovation, and customer interactivity. It’s no longer, “Should we use AI?” but “How fast can we move it into our core strategy? AI is now a survival tool. Financial services, healthcare, retail companies, and manufacturers use it to forecast trends, automate processes, and personalize experiences. Those who wait for AI to “mature” will face an increasingly compounding disadvantage in terms of cost, speed, and capability compared to early adopters. Click here: https://eularis.com/why-companies-that-wait-for-ai-to-mature-are-falling-behind/
Eularis provides a complete biopharma growth AI growth solution from strategy to full implementation. With 20 years of pharmaceutical ai implementation experience we help organizations deploy practical AI programs that improve decisions increase efficiency and drive measurable business growth.
Eularis supports companies in forecasting future growth areas for the pharmaceutical industry by evaluating patient demand, new scientific discoveries, digital and AI-driven development, collaborations, and regulatory access pathways. The entire process of uncovering markets and competitive edges is undertaken with the goal of making the pharmaceutical industry more sustainable in terms of growth and profitability.
AI is swiftly reshaping the pharmaceutical industry, transforming every facet from drug discovery to supply chain management with unparalleled speed and precision. The pace of adoption continues to accelerate, with projections that AI could unlock $60 – 110 billion in annual value for the industry (Mckinsey 2025).
Pharmaceutical Industry Marketing is raised by AI-based Eularis solutions to newer heights. We assist the pharmaceutical firms in automating the intelligent processes that lead to campaign optimization, customer behavior prediction, and hence, ROI maximization. Become a part of the marketing that is not only smart but also in tune with the needs of the healthcare professionals and that yields real business results.
Healthcare innovation is now at a crossroads, where the pursuit to make revolutionary strides forward is matched only by the challenge of making tools that actually help the people who pick them up and use them.
Pharma growth depends on spotting what’s coming next. Eularis supports organizations in assessing emerging trends for pharma growth, using the AI Transformation Engine to connect signals from the market with practical business decisions. The result is smarter planning, faster execution, and a clearer path to sustainable commercial impact.
Eularis delivers advanced AI solutions for the pharmaceutical industry that help organizations accelerate drug discovery, optimize clinical trials, and unlock actionable insights from complex life science data, enabling smarter decisions, improved efficiency, and better outcomes across the pharmaceutical value chain.
Eularis helps life science teams turn an AI solution in biopharma growth into reality by combining strategy creation, deployment planning, and real model implementation. Instead of one‑off projects, this full‑scope approach makes AI practical and measurable, helping organizations overcome challenges and unlock growth with tools and insights they can trust.
Everyone does digital marketing, and everybody is doing more of it these days. Consider these statistics:
Write a comment ...